Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Core Viewpoint - Lisata Therapeutics, Inc. has entered into a definitive agreement to be acquired by Kuva Labs Inc., with stockholders set to receive $5.00 per share in cash plus a contingent value right for an additional $1.00 per share, contingent on regulatory milestones [2][3][4]. Transaction Details - The merger agreement stipulates that Kuva will initiate a tender offer to acquire all outstanding shares of Lisata for $5.00 per share in cash, along with one contingent value right (CVR) per share [3]. - The CVR allows holders to receive an additional $1.00 per share if a New Drug Application for the product candidate certepetide is filed or accepted by the FDA within a specified timeframe [3]. - The transaction is expected to close in the second quarter of 2026, subject to customary offer conditions, including the tender of a majority of Lisata's outstanding shares [4]. Board of Directors Recommendation - The board of directors of Lisata has unanimously approved the merger agreement, determining it to be fair and in the best interests of the stockholders, and recommends that all stockholders accept the offer [6]. Post-Transaction Status - Upon completion of the transaction, Lisata will become part of Kuva, its common stock will be delisted from Nasdaq, and it will apply to deregister its common stock, ceasing to be a reporting company under U.S. securities laws [5]. Company Background - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, with its product candidate certepetide designed to enhance the targeting of anti-cancer drugs [8]. - Kuva Labs is a preclinical bioscience company developing a proprietary imaging platform aimed at improving cancer diagnosis and treatment [10].